69
Participants
Start Date
March 20, 2017
Primary Completion Date
June 14, 2021
Study Completion Date
June 14, 2021
Atezolizumab
"Arms A and B Atezolizumab will be administered at a dose of 840 milligrams (mg) prior to RO6874281 administration as an intravenous (IV) infusion on Days 1, 15, 29, and once in 2 weeks from Day 29 onwards. Doses in the extension part will be based on the maximum tolerated dose determined in the escalation part.~Arms C and D Atezolizumab will be administered at a dose of 1200mg as it is a Q3W schedule"
Bevacizumab
"Arms A and B Bevacizumab will be administered at a dose of 10 milligrams per kilogram (mg/kg) after the atezolizumab administration, and prior to RO6874281 administration as an IV infusion on Days 15, 29, and once in 2 weeks from Day 29 onwards.~In Arm D, Bevacizumab will be administered at a dose of 15mg/kg on Day 8 of Cycle 2 and on Day 8 of each consecutive cycle."
RO6874281
"Arms A and B RO6874281 will be administered as an IV infusion on Days 1, 8, 15, 22, and 29, and once in 2 weeks from Day 29 onwards. Starting dose of RO6874281 will be 5 mg, and will be increased subsequently. Doses in the extension part will be based on the maximum tolerated dose determined in the escalation part.~In Arms C and D, RO will be administered on Q3W schedule at the dose defined in the dose escalation part"
Herlev Hospital; Afdeling for Kræftbehandling, Herlev
University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
Fondazione IRCCS Policlinico San Matteo, Oncologia, Pavia
Hospital Ramon y Cajal; Servicio de Oncologia, Madrid
START Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid
Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona
Institut Claudius Regaud; Departement Oncologie Medicale, Toulouse
Universita di Modena e Reggio Emilia;Dipartimento di Oncologia ed Ematologia, Modena
Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia
Northwestern Center for Clinical Research; Cancer Center, Chicago
Centre Léon Bérard - Centre régional de lutte contre le cancer Rhône-Alpes, Lyon
Universitätsklinikum Tübingen; Klinik für Urologie, Tübingen
Uniklinikum, Comprehensive Cancer Center Mainfranken; Interdisziplinäres Studienzentrum mit ECTU, Würzburg
Yale Cancer Center; Medical Oncology, New Haven
Princess Margaret Cancer Center, Toronto
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Hospital del Mar; Servicio de Oncologia, Barcelona
Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona
Hospital Clínic i Provincial; Servicio de Oncología, Barcelona
Barts & London School of Med; Medical Oncology, London
The Christie, Manchester
Southampton General Hospital; Medical Oncology, Southampton
Hoffmann-La Roche
INDUSTRY